Canaccord Genuity Group Has Lowered Expectations for Neuronetics (NASDAQ:STIM) Stock Price

Neuronetics (NASDAQ:STIM) had its price target dropped by equities research analysts at Canaccord Genuity Group from $7.00 to $3.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective points to a potential upside of 106.90% from the company’s previous close.

Several other equities analysts have also recently weighed in on STIM. Wall Street Zen raised Neuronetics from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Neuronetics in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $3.00.

Neuronetics Stock Down 4.3%

STIM stock opened at $1.45 on Thursday. The firm’s 50-day simple moving average is $1.60 and its 200 day simple moving average is $2.03. The company has a quick ratio of 2.09, a current ratio of 2.02 and a debt-to-equity ratio of 2.51. The stock has a market cap of $100.45 million, a PE ratio of -2.46 and a beta of 0.87. Neuronetics has a fifty-two week low of $0.80 and a fifty-two week high of $5.05.

Neuronetics (NASDAQ:STIM) last issued its quarterly earnings results on Tuesday, March 17th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02. Neuronetics had a negative return on equity of 121.26% and a negative net margin of 26.15%.The firm had revenue of $41.78 million during the quarter, compared to analyst estimates of $40.84 million. As a group, sell-side analysts predict that Neuronetics will post -1.13 EPS for the current year.

Insider Activity at Neuronetics

In related news, major shareholder Jorey Chernett bought 607,400 shares of Neuronetics stock in a transaction that occurred on Wednesday, March 18th. The stock was purchased at an average cost of $1.35 per share, with a total value of $819,990.00. Following the purchase, the insider owned 8,123,804 shares in the company, valued at approximately $10,967,135.40. This trade represents a 8.08% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Keith J. Sullivan sold 40,976 shares of the firm’s stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $1.55, for a total transaction of $63,512.80. Following the completion of the transaction, the chief executive officer directly owned 1,567,012 shares of the company’s stock, valued at approximately $2,428,868.60. This trade represents a 2.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders bought 1,588,400 shares of company stock valued at $2,034,450 and sold 104,307 shares valued at $164,097. 8.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Neuronetics

Large investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd grew its holdings in shares of Neuronetics by 2,667.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 69,756 shares of the company’s stock worth $96,000 after purchasing an additional 67,235 shares in the last quarter. Aristides Capital LLC bought a new stake in shares of Neuronetics during the fourth quarter worth about $188,000. Invesco Ltd. increased its position in Neuronetics by 80.0% in the 4th quarter. Invesco Ltd. now owns 58,940 shares of the company’s stock valued at $81,000 after acquiring an additional 26,194 shares during the period. XTX Topco Ltd raised its position in shares of Neuronetics by 992.6% during the fourth quarter. XTX Topco Ltd now owns 314,194 shares of the company’s stock worth $434,000 after acquiring an additional 285,438 shares during the last quarter. Finally, Caption Management LLC raised its stake in Neuronetics by 571.4% during the fourth quarter. Caption Management LLC now owns 92,501 shares of the company’s stock worth $128,000 after buying an additional 78,723 shares during the last quarter. Institutional investors own 53.59% of the company’s stock.

Neuronetics News Summary

Here are the key news stories impacting Neuronetics this week:

• Positive Sentiment: Major insider buying: Jorey Chernett (a major shareholder) increased his stake with multiple purchases over March 17–19 totaling roughly 1.59M shares across filings, boosting ownership and signaling insider confidence. SEC Form 4 filing Investing.com coverage
• Positive Sentiment: Q4 results modestly beat expectations: EPS of ($0.10) vs. (~$0.12) est. and revenue $41.8M vs. $40.8M expected — a near‑term operational positive but the company remains unprofitable. Earnings call transcript
• Neutral Sentiment: Mixed analyst and institutional profile: MarketBeat notes one Buy and one Sell rating, a consensus “Hold,” active institutional turnover, and wide variance in targets — underlines divergent views and liquidity sensitivity for this small‑cap stock. MarketBeat coverage
• Negative Sentiment: Price‑target reduction from Canaccord: Canaccord cut its target from $7 to $3 (still a Buy), narrowing perceived upside and likely weighing on sentiment despite the maintained rating. Benzinga report
• Negative Sentiment: Short‑term sell pressure / headline reaction: AAII and other outlets highlighted a multi‑percent intraday decline (around 5%), attributing it to the mix of analyst action, profit‑taking after recent moves, and the company’s continued negative margins and leverage. AAII article

Neuronetics Company Profile

Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.